Vir Biotechnology (NASDAQ: VIR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.780 | 3.850 | 0.0700 | ||||
REV | 836.970M | 1.232B | 395.030M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vir Biotechnology (NASDAQ: VIR) through any online brokerage.
Other companies in Vir Biotechnology’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Karuna Therapeutics (NASDAQ:KRTX), Cerevel Therapeutics Hldg (NASDAQ:CERE) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Vir Biotechnology (NASDAQ: VIR) was reported by HC Wainwright & Co. on Thursday, May 12, 2022. The analyst firm set a price target for 125.00 expecting VIR to rise to within 12 months (a possible 385.63% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Vir Biotechnology (NASDAQ: VIR) is $25.74 last updated Today at June 30, 2022, 5:24 PM UTC.
There are no upcoming dividends for Vir Biotechnology.
Vir Biotechnology’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Vir Biotechnology.
Vir Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.